Rationale for multiple risk intervention. The need to move from theory to practice

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 985-997

  Erhardt, Leif R ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Blood pressure; Cardiovascular disease; Hyperlipidemia; Implementation; Insulin resistance; Metabolic syndrome; New onset diabetes; Obesity; Risk factor management; Risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOBESITY AGENT; ATENOLOL; ATORVASTATIN; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; RAMIPRIL; ROSIGLITAZONE; ROSUVASTATIN; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIACYLGLYCEROL; VALSARTAN;

AEROBIC EXERCISE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GOVERNMENT REGULATION; HEALTH EDUCATION; HEART INFARCTION; HUMAN; HYPERTENSION; IMMOBILIZATION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIFESTYLE MODIFICATION; METABOLIC DISORDER; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRESCRIPTION; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SCREENING TEST; SMOKING CESSATION; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; LIFE STYLE; MASS SCREENING; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 38149044844     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. [Anonymous] No authors listed. 2005. After the diagnosis: adherence and persistence with hypertension therapy. Am J Manag Care, 11:S395-S399.
2. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. 2005. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism, 54:1065-74.
3. Backlund L, Bring J, Strender L-E. 2004. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients? Primary Health Care Research and Development, 5:145-52.
4. Baena Diez JM, Alvarez PB, Pinol FP, et al. 2002. [Association between clustering of cardiovascular risk factors and the risk of cardiovascular disease]. Rev Esp Salad Publica, 76:7-15.
5. British Cardiac Society, [BCS], British Hypertension Society, Diabetes UK, et al. 2005. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart, 91(Suppl 5):v1-52.
6. Brown MJ. 2002. MRC/BHF Heart Protection Study. Lancet, 360:1782-4.
7. Buchanan TA, Xiang AH, Peters RK, et al. 2002, Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes, 51:2796-803.
8. Canadian Hypertension Society, [CHS]. 2005. CHEP Recommendations for the management of hypertension [online]. Accessed on April 10, 2007. URL: www.hypertension.ca/recommendations_2005/ultrashortexecsummary2005.pdf
9. Cheung BM, Ong KL, Man YB, et al. 2006. Prevalence of the metabolic syndrome in the United States national health and nutrition examination survey 1999-2002 according to different defining criteria. J Clin Hypertens (Greenwich), 8:562-70.
10. Chiasson JL, Josse RG, Gomis R, et al. 2003. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA, 290:486-94.
11. Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206-52.
12. Conroy RM, Pyorala K, Fitzgerald AP, et al. 2003. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J, 24:987-1003.
13. Csaszar A, Kekes E, Abel T, et al. 2006. Prevalence of metabolic syndrome estimated by International Diabetes Federation criteria in a Hungarian population. Blood Press, 15:101-6.
14. Dahlof B, Devereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:995-1003.
15. Daskalopoulou SS, Mikhailidis DP, Elisaf M. 2004. Prevention and treatment of the metabolic syndrome. Angiology, 55:589-612.
16. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. 2003. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil, 10:S1-S10.
17. Doll R, Peto R, Wheatley K, et al. 1994. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ, 309:901-11.
18. DREAM Trial Investigators. 2006. Effect of Ramipril on the incidence of diabetes. N Engl J Med, 355:Sep 15 [Epub ahead of print].(b)
19. DREAM Trial Investigators. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 368:1096-105.
20. Elabbassi WN, Haddad HA. 2005. The epidemic of the metabolic syndrome. Saudi Med J, 26:373-5.
21. El-Atat F, Mc/Farlane SI, Sowers JR. 2006. Diabetes, hypertension and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep, 6:215-23.
22. Epstein M. 2006. Diabetes and hypertension: the bad companions. J Hypertens, 15:S55-S62.
23. Erhardt LR, Gotto A Jr. 2006. The evolution of European guidelines: changing the management of cholesterol levels. Atherosclerosis, 185:12-20.
24. ESH/ESC Guidelines Committee. 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 21:1011-53.
25. Ford ES, Giles WH, Mokdad AH. 2004. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care, 27:2444-9.
26. Ford ES. 2005. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US Diabetes Care, 28:2745-9.
27. Giles TD, Berk BC, Black HR, et al. 2005. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich), 7:505-12.
28. Goldman DP, Joyce GF, Karaca-Mandic P. 2006. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care, 12:21-8.
29. Greenland P, Knoll MD, Stamler J, et al. 2003. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA, 290:891-7.
30. Grandy SM. 2005. Metabolic syndrome: therapeutic considerations. Handb Exp Pharmacol, 170:107-33.
31. Grundy SM. 2006. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol, 47:1093-100.
32. Gu D, Gupta A, Muntner P, et al. 2005. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation, 112:658-65.
33. Hackam DG, Anand SS. 2003. Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence. JAMA, 290:932-40.
34. Hansen DG, Gichangi A, Vach W, et al. 2007. Early discontinuation: more frequent among general practitioners with high levels of prescribing. Eur J Clin Pharmacol, 63:861-5.
35. Hanson RL, Imperatore G, Bennett PH, et al. 2002. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes, 51:3120-7.
36. Hedley AA, Ogden CL, Johnson CL, et al. 2004. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA, 291:2847-50.
37. Hubert HB, Feinleib M, McNamara PM, et al. 1983. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation, 67:968-77.
38. International Diabetes Federation, [IDF]. 2006. The IDF consensus worldwide definition of the metabolic syndrome. Accessed on April 10, 2007. URL: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf
39. Jansson JH, Boman K, Messner T. 2003. Trends in blood pressure, lipids, lipoproteins and glucose metabolism in the Northern Sweden MONICA proj ect 1986-99. Scand J Public Health Suppl, 61:43-50.
40. Julius S, Kjeldsen SE, Weber M, et al. 2004. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363:2022-31.
41. Kitabchi AE, Ternprosa M, Knowler WC, et al. 2005. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes, 54:2404-14.
42. Klein S. 2004. Long-term pharmacotherapy for obesity. Obes Res, 12 (Suppl):163S-166S.
43. Knowler WC, Barrett-Connor E, Fowler SE, et al. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346:393-403.
44. Koh-Banedee P, Wang Y, Hu FB, et al. 2004. Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men. Am J Epidemiol, 159:1150-9.
45. Kshirsagar AV, Carpenter M, Bang H, et al. 2006. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med, 119:133-41.
46. Laaksonen DE, Lakka HM, Niskanen LK, et al. 2002. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol, 156:1070-7.
47. Lakka HM, Laaksonen DE, Lakka TA, et al. 2002. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288:2709-16.
48. LaRosa JC, Grundy SM, Waters DD, et al. 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 352:1425-35.
49. Li Z, Maglione M, Tu W, et al. 2005. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med, 142:532-46.
50. Lindholm LH, Persson M, Alaupovic P, et al. 2003. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens, 21:1563-74.
51. Lithell H, Hansson L, Skoog I, et al. 2003. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens, 21:875-86.
52. Mancia G. 2006. Total cardiovascular risk: a new treatment concept. J Hypertens Suppl, 24:S17-S24.
53. McCall KL, Craddock D, Edwards K. 2006. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis. Pharmacotherapy, 26:1297-306.
54. McLaughlin T, Abbasi F, Cheal K, et al. 2003. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med, 139:802-9.
55. McLaughlin T, Allison G, Abbasi F, et al. 2004. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism, 53:495-9.
56. Mosca L, Linfante AH, Benjamin EJ, et al. 2005. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation, 111:499-510.
57. NCEP Expert Panel. 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106:3143-421.
58. Ninomiya JK, L'Italien G, Criqui MH, et al. 2004. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation, 109:42-6.
59. Nissen SE, Nicholls SJ, Sipahi I, et al. 2006. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA, 295:1556-65.
60. PROGRESS Collaborative Group. 2001. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 358:1033-41.
61. Schrier RW, Estacio RO, Esler A, et al. 2002. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int, 61:1086-97.
62. Sever PS, Dahlof B, Poulter NR, et al. 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 361:1149-58.
63. Shinitzky HE, Kub J. 2001. The art of motivating behavior change: the use of motivational interviewing to promote health. Public Health Nurs, 18:178-85.
64. Sowers JR. 2006. Recommendations for special populations: diabetes melitus and the metabolic syndrome. Am J Hypertens, 16:S41-S45.
65. Stamler J, Vaccaro O, Neaton JD, et al. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16:434-44.
66. Suk SH, Sacco RL, Boden-Albala B, et al. 2003. Abdominal obesity and risk of ischernic stroke: the Northern Manhattan Stroke Study. Stroke, 34(7):1586-92.
67. Thomas F, Rudnichi A, Bach AM, et al. 2001. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension, 37:1256-61.
68. Tolonen H, Keil U, Ferrario M, Evans A. 2005. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. Int J Epidemiol, 34:181-92.
69. Torgerson JS, Hauptman J, Boldrin MN, et al. 2004. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27:155-61.
70. Vitale C, Marazzi G, Volterrani M, et al. 2006. Metabolic syndrome. Minerva Med, 97:219-29.
71. Volpe M, Tocci G. 2006. Integrated cardiovascular risk management for the future: lessons learned ftom the ASCOT trial. Aging Clin Exp Res, 17:46-53.
72. Wagh A, Stone NJ. 2004. Treatment of metabolic syndrome. Expert Rev Cardiovasc Ther, 2:213-28.
73. Whitworth JA. 2003. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983-92.
74. Wild SH, Byrne CD. 2005. The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In: Byrne CD, Wild SH (eds). The Metabolic Syndrome. Chichester: John Wiley & Sons, Ltd;, 1-43.
75. Williams B, Poulter NR, Brown MJ, et al. 2004. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens, 18:139-85.
76. Wiviott SD, de Lemos JA, Cannon CP, et al. 2006. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation, 113:1406-14.
77. World Health Organization, [WHO]. 2002. The European Health Report. Accessed on April 10, 2007. URL: http://www.euro.who.int/ europeanhealthreport
78. Yusuf S, Hawken S, Ounpuu S, et al. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 364:937-52.
79. Yusuf S, Pfeffer MA, Swedberg K, et al. 2003. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 362:777-81.
80. Yusuf S, Sleight P, Pogue J, et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342:145-53.
81. Zieve FJ. 2004. The metabolic syndrome: diagnosis and treatment. Clin Cornerstone, 6(Suppl 3):S5-S13.